Free Trial

Pharming Group (PHAR) Competitors

Pharming Group logo
$13.60 -1.21 (-8.17%)
Closing price 03:51 PM Eastern
Extended Trading
$13.52 -0.07 (-0.55%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PHAR vs. SRRK, VKTX, MIRM, LNTH, ADMA, ACAD, ZLAB, QURE, CGON, and AAPG

Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), ADMA Biologics (ADMA), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), uniQure (QURE), CG Oncology (CGON), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.

Pharming Group vs. Its Competitors

Scholar Rock (NASDAQ:SRRK) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Scholar Rock has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

In the previous week, Scholar Rock had 4 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Scholar Rock and 5 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.71 beat Scholar Rock's score of -0.01 indicating that Pharming Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pharming Group
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Scholar Rock presently has a consensus target price of $48.50, suggesting a potential upside of 63.41%. Pharming Group has a consensus target price of $30.00, suggesting a potential upside of 120.59%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07
Pharming Group
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Scholar Rock has a net margin of 0.00% compared to Pharming Group's net margin of -2.19%. Pharming Group's return on equity of -3.31% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -127.11% -90.09%
Pharming Group -2.19%-3.31%-1.78%

Pharming Group has higher revenue and earnings than Scholar Rock. Pharming Group is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$33.19M85.96-$246.29M-$2.91-10.20
Pharming Group$339.84M2.74-$11.84M-$0.13-104.62

Summary

Scholar Rock beats Pharming Group on 10 of the 17 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHAR vs. The Competition

MetricPharming GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$931.80M$3.42B$6.14B$10.76B
Dividend YieldN/A2.26%5.71%4.83%
P/E Ratio-104.6223.3029.8028.54
Price / Sales2.74271.63499.06189.72
Price / Cash176.7245.1236.6160.67
Price / Book4.1810.4112.016.61
Net Income-$11.84M-$52.62M$3.32B$276.82M
7 Day Performance-2.86%2.10%1.78%2.07%
1 Month Performance-8.29%10.86%6.28%2.62%
1 Year Performance63.86%13.59%61.13%32.86%

Pharming Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHAR
Pharming Group
2.5868 of 5 stars
$13.60
-8.2%
$30.00
+120.6%
+54.3%$931.80M$339.84M-104.62280Gap Down
SRRK
Scholar Rock
4.4347 of 5 stars
$34.28
-13.1%
$48.60
+41.8%
+2.5%$3.79B$33.19M-11.78140Gap Down
High Trading Volume
VKTX
Viking Therapeutics
4.0606 of 5 stars
$33.91
+1.0%
$86.42
+154.8%
-43.8%$3.77BN/A-22.1620Trending News
Earnings Report
Analyst Downgrade
Analyst Revision
Gap Up
MIRM
Mirum Pharmaceuticals
3.7564 of 5 stars
$72.17
-0.7%
$76.50
+6.0%
+80.7%$3.65B$336.89M-59.64140
LNTH
Lantheus
4.5997 of 5 stars
$54.59
+2.0%
$74.50
+36.5%
-48.9%$3.64B$1.53B14.52700Trending News
ADMA
ADMA Biologics
3.6304 of 5 stars
$14.55
+0.1%
$27.67
+90.1%
-2.8%$3.47B$426.45M16.92530News Coverage
Positive News
Analyst Downgrade
ACAD
ACADIA Pharmaceuticals
3.936 of 5 stars
$20.06
flat
$29.12
+45.2%
+52.1%$3.38B$957.80M15.08510News Coverage
Analyst Forecast
ZLAB
Zai Lab
2.5822 of 5 stars
$31.23
+3.3%
$56.35
+80.4%
-3.2%$3.38B$398.99M-15.311,869News Coverage
Analyst Forecast
Analyst Revision
QURE
uniQure
2.3649 of 5 stars
$62.02
+0.7%
$71.75
+15.7%
+822.0%$3.38B$27.12M-15.82500Analyst Forecast
Gap Up
CGON
CG Oncology
2.3208 of 5 stars
$42.96
-0.7%
$58.82
+36.9%
+17.9%$3.30B$1.14M-24.2761Analyst Forecast
AAPG
Ascentage Pharma Group International
N/A$36.45
+4.3%
N/AN/A$3.26B$390.60M0.00600

Related Companies and Tools


This page (NASDAQ:PHAR) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners